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Abstract
The current knowledge assigns a crucial role to the Rho GTPases
family (Rho, Rac, Cdc42) in the complex transductive pathway
leading to skeletal muscle cell differentiation. Their exact function
in myogenesis, however, remains largely undefined. The protein
toxin CNF1 was herein employed as a tool to activate Rho, Rac
and Cdc42 in the myogenic cell line C2C12. We demonstrated that
CNF1 impaired myogenesis by affecting the muscle regulatory
factors MyoD and myogenin and the structural protein MHC
expressions. This was principally driven by Rac/Cdc42 activation
whereas Rho apparently controlled only the fusion process. More
importantly, we proved that a controlled balance between Rho and
Rac/Cdc42 activation/deactivation state was crucial for the correct
execution of the differentiation program, thus providing a novel
view for the role of Rho GTPases in muscle cell differentiation.
Also, the use of Rho hijacking toxins can represent a new strategy
to pharmacologically influence the differentiative process.
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Introduction
Skeletal muscle cell differentiation is a multistep process that
involves permanent withdrawal from the cell cycle, activation
of muscle-specific genes, and fusion of differentiated myo-
cytes in multinucleated myotubes. Terminal differentiation,
both in vivo and in vitro, is regulated by the activity of muscle-
restricted regulatory factors (MRFs) belonging to the basic
helix–loop–helix (bHLH) family, in concert with members of
the E2A and myocyte enhancer factor 2 (MEF2) families.1,2
The four members of MRF family, MyoD, Myf5, myogenin and
MRF4, activate transcription of target genes by binding to
sequence-specific elements, present in muscle regulatory
and structural gene enhancers.3 Besides governing transcrip-
tion of muscle-specific genes, MRFs also control irreversible
withdrawal from the cell cycle by interacting with key cell cycle
regulators.4–6 Although several signal transduction pathways
and protein–protein interactions regulating MRF expression
and activity have been described, how these processes are
integrated represents a major challenge in muscle differentia-
tion research.
The evolutionary conserved small GTPases of Rho family,
known primarily for their role in actin cytoskeleton organiza-
tion, are involved in a large variety of biological functions,7
controlling nuclear signalling, gene transcription and cell
differentiation, including skeletal muscle differentiation. The
Rho GTPases, which belong to the Ras superfamily, are
molecular switches that cycle between an inactive GDP-
bound and an active GTP-bound state. The Rho family
encompasses the three subfamilies Rho, Rac and Cdc42 that
differentially regulate the commitment to myogenesis. It is still
under debate, however, how exactly each member of the Rho
family influences the muscle differentiation and also which
transductive pathway is regulated. Rho A has been reported
to positively regulate MyoD expression and skeletal muscle
cell differentiation, as it has been demonstrated to be required
for serum response factor (SRF)-mediated activation of
several muscle-specific gene promoters.8,9 Concerning
Rac1 and Cdc42, their role on skeletal myogenesis appears
to be controversial. On the one hand, expression of
constitutively active forms of Rac1 and Cdc42Hs inhibits
myogenesis10,11 and they do that through the activation of
JNK pathway.11 Also, Rac1 activation affects terminal
differentiation by interfering with cell cycle withdrawal.12 On
the other hand, inhibition of Rac1 and Cdc42Hs interferes with
myogenesis,11,13 and this corresponds to a decrease in p38
MAPK activity.11 Moreover, Takano et al.13 reported that both
RhoA and Cdc42/Rac1 subfamilies play a positive role in the
differentiation of C2C12 myoblasts. Indeed, expression of
constitutively activated forms of Rho family members induced
transcription of muscle-specific genes.
The Rho GTPases represent a target of growing interest for
bacterial protein toxins, which in their turn represent invalu-
able tools for cell biology studies aimed at defining Rho
functions.14 Herein we used a protein toxin from Escherichia
coli, named cytotoxic necrotizing factor 1 (CNF1), which
specifically activates Rho, Rac and Cdc42 by catalyzing their
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deamidation at a specific glutamine residue at the level of the
switch 2 domain.15–17 Importantly, CNF1 can recognize the
glutamine residue included in a specific amino-acidic se-
quence that is present only in members of the Rho family.17
Due to its peculiar activating property on Rho GTPases, CNF1
has already contributed to the investigation of relevant cellular
processes, such as macropinocytosis,18 cell motility19 or NK-
mediated cytotoxicity.20
Therefore, in the present study, we have utilized CNF1
as a tool to modulate Rho GTPase activity in the mouse
myogenic cell line C2C12, and analyzed how it could influence
muscle cell differentiation in relationship to the differential
activation of the Rho family members as compared with
the physiological process. The aim was to contribute to the
definition of the puzzling role played by the Rho GTPases
in muscle cells.
Results
CNF1 hinders myotube formation in C2C12 cells
In this work, we employed the Rho GTPase-activating
bacterial toxin CNF1 to approach the differentiation of
C2C12 cells, the so far best characterized myogenic cell line.
In the presence of a high concentration of serum, these cells
proliferate as an undifferentiated population, while following
serum deprivation they permanently withdraw from the cell
cycle, undergo terminal differentiation and fuse into multi-
nucleated myotubes. It is known that CNF1 causes an
impressive rearrangement of the actin cytoskeleton in most
cell lines studied so far,20,21 thus representing an extremely
powerful tool to study those cellular functions that rely on actin
network dynamics. Hence, our investigation started by
analyzing the effects of CNF1 on the ultrastructure and
actin cytoskeleton organization of C2C12 cells, being the
cytoskeleton architecture crucial during the muscle cell
differentiation.
In order to investigate how myogenic cells morphologically
respond to the toxin, C2C12 cells were cultivated in growth
medium (GM) for 24 h and then challenged with CNF1 (GM/
CNF1) for further 48 h or shifted in differentiation medium
(DM) for 72 h, in the presence (DM/CNF1) or absence (DM) of
CNF1 (Figure 1). As shown by scanning electron microscopy
(Figure 1a–d), CNF1 caused the enlargement and spreading
of proliferating myoblasts (compare Figure 1a with Figure 1b),
without altering the general cell morphology. In contrast, the
presence of the toxin in DM impaired the phenotypic
differentiation of myoblasts into myotubes (shown in
Figure 1c), CNF1-treated cells showing a smooth myoblast-
like surface, and appearing larger than control myoblasts
(Figure 1d). As expected, such morphological alterations
reflected profound modifications of the actin cytoskeletal
architecture induced by CNF1 treatment (Figure 1e–h). In
fact, whereas C2C12 myoblasts (GM) were characterized
by short stress fibres and membrane ruffles (Figure 1e),
CNF1-treated myoblasts (GM/CNF1) displayed more evident
stress fibres, but not ruffles (Figure 1f). When grown in
DM for 72 h, the majority of C2C12 cells fused into multi-
nucleated myotubes with the actin cytoskeleton arranged in
long bundles crossing the myotube cell body, rather than
in stress fibres (Figure 1g). The addition of CNF1 to the
cells since the beginning of the incubation time in DM
(DM/CNF1) prevented the morphological differentiation of
myoblasts in myotubes. Cells, indeed, appeared mostly
mononucleated with the actin cytoskeleton organized in
stress fibres, resembling cultures in GM conditions
(Figure 1h).
The evidence presented clearly demonstrates that CNF1 is
able to perturb the physiological actin cytoskeleton organiza-
tion in myogenic cells, as occurs in other cell types,20,21 and to
dramatically impair myotube formation upon differentiative
stimuli.
Figure 1 CNF1 impairs myotube formation and reorganizes the actin
cytoskeleton in C2C12 cells. C2C12 cells were cultivated in growth medium
(GM) (a, e) for 24 h and then challenged with CNF1 (GM/CNF1) (b, f) for further
48 h or shifted in differentiation medium (DM) for 72 h, in the presence (DM/
CNF1) (d, h) or absence (DM) (c, g) of CNF1. (a–d) Scanning electron
microscopy (SEM) analysis shows that CNF1 causes the enlargement and
spreading of proliferating myoblasts (compare a with b), without altering the
general cell morphology. While cells maintained in DM (c) for 72 h fuse to form
multinucleated myotubes, CNF1-treated cells (d) are unable to form myotubes
and show a smooth myoblast-like surface phenotype, although appearing larger
than control myoblasts (a). (e–h) Fluorescence microscopy analysis of C2C12
cells co-stained with fluoresceine-conjugated-phalloidin, to define F-actin
organization, and with the nuclear dye DAPI. Note that CNF1-treated myoblasts
(f) show more evident stress fibres than control cells (e). In DM (g), cells form
multinucleated myotubes with actin organized in long and thick bundles. When
CNF1 is added simultaneously to the shift in DM (h), most cells appears
mononucleated and with prominent stress fibres. Many collapsed myotubes
(arrows) intensively stained with FITC-phalloidin are detectable. In (e–h),
individual pictures of the same field, taken with a DC camera, were merged using
a LEICA Microsystems Imaging Equipment. Bar¼ (a–d) 40 mm; (e–h) 20 mm
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CNF1 treatment interferes with muscle-specific
gene expression in C2C12 cells
Loss of competence of CNF1-treated C2C12 to form multi-
nucleated myotubes would not necessarily correspond to lack
of myogenic biochemical differentiation. Indeed, examples of
biochemical differentiation without fusion have been reported
for Myc-transformed C2C12 cells and MRF-converted
NIH3T3 cells.22,23 Based on this notion, we wondered
whether, behind the inability to form multinucleated myotubes,
CNF1-treated C2C12 cells were still able to accomplish the
differentiative program and express skeletal muscle-asso-
ciated markers when induced to differentiate. Hence, we first
investigated the expression of skeletal muscle myosin heavy
chain (MHC), performing a qualitative analysis by indirect
immunofluorescence. Figure 2a shows that C2C12 cells
grown in DM for 72 h underwent terminal differentiation, fused
into multinucleated myotubes and accumulated MHC with
high efficiency (DM), while MHC expression was severely
reduced by the presence of CNF1 (DM/CNF1). In this last
condition, the majority of MHC-expressing cells was mono-
nucleated. The latter phenotype was further evidenced by the
fusion index evaluation of C2C12 cells maintained in DM or
DM plus CNF1 (Figure 2b). In fact, untreated cells displayed a
considerably high fusion ability (more than 60%) while the
fusion index of C2C12 cells under differentiation conditions in
the presence of CNF1 never exceeded 15%. Furthermore,
such a minor percentage of multinucleated cells could be
ascribed to the presence of polycarions (arrows in Figure 2a)
instead of true myotubes.
Western blot analysis confirmed the CNF1 capacity of
lessening the expression of MHC (Figure 3a), a decrease due
to the interference of the toxin with the specific mRNA
accumulation, as demonstrated by data from Northern blot
experiments (Figure 3b). It is largely documented that the
expression of many myogenic differentiation-associated
Figure 2 CNF1 dramatically decreases the ability of C2C12 cells to fuse into
MHC-positive myotubes. (a) Immunofluorescence analysis of skeletal myosin
heavy chain (MHC), the typical marker of terminally differentiated muscle cells.
MHC protein is highly expressed in C2C12 cells grown in DM for 72 h and virtually
absent in most cells in CNF1-treated cultures, although still detectable in the rare
polycarions (arrows). (b) Graph showing the fusion index of C2C12 cells grown in
DM for 72 h in the presence (DM/CNF1) or in the absence (DM) of CNF1. Cells
were stained for MHC and the fusion index was defined as the percentage of
nuclei belonging to MHC-positive cells with three or more nuclei. Note that CNF1
dramatically reduces the ability of cells to fuse into multinucleated myotubes. The
values reported in the graph are the means7standard deviations (S.D.) from
three separate experiments performed in duplicate. In (a), individual pictures of
the same field, taken with a DC camera, were merged using a LEICA
Microsystems Imaging Equipment. Bar¼ 20 mm
Figure 3 CNF1 downregulates the expression of MHC and of the myogenic
regulatory factors (MRFs) MyoD and Myogenin. (a) Western blot analysis of
C2C12 cells grown in DM for 72 h in the presence or in the absence of CNF1.The
blots clearly show the ability of CNF1 to interfere with the expression of MHC,
MyoD and myogenin. (b) Northern blot analysis of C2C12 cells grown in the same
conditions as in (a), showing a negative effect of CNF1 on the accumulation of
MHC, MyoD and myogenin mRNAs. Equal protein (a) and mRNA (b) loading was
confirmed by detecting b-tubulin and GAPDH, respectively
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genes, including MHC, is regulated by the activity of muscle-
restricted transcription factors belonging to the MyoD family,
including MyoD, Myf5, Myogenin and MRF4.2 In turn, the
expression of myogenin is directly induced by MyoD at the
onset of muscle differentiation.24 On this notion, we wondered
whether the impairment of C2C12 myoblasts differentiation by
CNF1 could reflect a defect in the expression of muscle
regulatory factors (MRFs). For this purpose, the accumulation
of MyoD and myogenin proteins at 72 h in DM was analyzed
by Western blot. Data presented in Figure 3a clearly showed
that the presence of CNF1 in the differentiative medium
considerably reduced the expression of MyoD protein. As
expected, also myogenin was downregulated, being this gene
a direct target of MyoD trans-activating function. As for MHC
expression, Northern blot experiments indicated that the
downregulation of MyoD and Myogenin was a consequence of
the marked reduction in the respective mRNA levels
(Figure 3b).
Taken together, these results highlight that the dramatic
effects exerted by CNF1 on the morphological differentiation
of C2C12 cells are paralleled by an interference with the
biochemical differentiation.
CNF1 induces a sustained activation of RhoA,
Rac1 and Cdc42 GTPases in C2C12 cells
It is widely reported that the characterizing function of CNF1 is
to permanently activate Rho, Rac and Cdc42 GTPases in all
cell systems where its effect has been studied, but the timing
and level of activation of distinct members of Rho GTPase
family differ depending on the cell type.19,25,26 Furthermore,
although many data have been accumulated on the effects of
activated or dominant-negative forms of such GTPases on the
skeletal muscle differentiation in vitro,8–13,27 very few is known
about the activation state and dynamics of RhoA, Rac1 and
Cdc42 during myogenic differentiation process. Hence, in
order to establish a relationship between the lack of
differentiation potential in CNF1-treated C2C12 cells and the
activation of distinct member(s) of Rho GTPases family
targeted by CNF1, we monitored the activity of Rho GTPases
during the differentiative process, either in control C2C12 cells
or in CNF1-treated cultures. For this purpose, cells were
cultured in DM or in DM plus CNF1 for different period lengths
(3, 24 and 72 h) and, at each time point, the amount of GTP-
bound RhoA, Rac1 and Cdc42 GTPases was detected by a
pull-down assay (see Materials and methods). The results
obtained are reported in Figure 4. The immmunoblots (line 1)
were analyzed by densitometry (see Materials and methods)
and normalized as a function of the total proteins loaded in the
assay (histograms in line 2).
As shown in Figure 4a, while a very small amount of GTP-
bound RhoA was detectable in proliferating myoblasts, the
active form of the protein virtually disappeared in differentiat-
ing cells (DM 3 and 24 h) and returned to the level observed in
myoblasts, in differentiated myotubes (DM 72 h). This would
suggest the necessity of a ‘switch off’ of the RhoA protein
during the first steps of the differentiative process. CNF1 was
able to induce a dramatic and time-dependent activation of the
protein, being the amount of RhoA-GTP significantly and
progressively augmented starting from the first hours until
72 h of culture in the differentiative medium (Figure 4a). Rac1
GTPase (Figure 4b) was active in proliferating C2C12 cells
(GM) and in the first 24 h of culture in DM (DM 3 and 24 h),
while the amount of Rac1-GTP dramatically decreased after
72 h in DM, when cultures were fully differentiated. This
kinetics suggests that Rac1 GTPase should be inactivated in
order to achieve the terminal differentiation of myoblasts in
myotubes. In cells grown in DM, CNF1 induced a time-
dependent increase and sustained activation of the Rac1
GTPase, being the protein still active following 72 h of
culture in DM. A small amount of Cdc42-GTP (Figure 4c)
was already present in proliferating myoblasts. When cells
were shifted in DM, the activation level of this GTPase
significantly increased and remained elevated until 72 h.
CNF1 was not able to further increase the levels of Cdc42
activated form during the first 24 h of culture in DM, while,
following 72 h, the amount of activated Cdc42 in DM/CNF1
was dramatically enhanced with respect to untreated C2C12
cells (Figure 4c).
The histograms reported in line 3 of Figure 4 illustrate the
difference between CNF1-induced Rho GTPases activation
and the activity of the same proteins throughout the
differentiation process of C2C12 cells, and underline the
diverse activation kinetics imposed by CNF1. This analysis
demonstrated that: (A) RhoA was activated by CNF1 since the
first hours of incubation with the toxin (3 h); (B) Rac1 activation
began following 24 h of CNF1-exposure while (C) an increase
of CNF1-activated Cdc42 was observable only at 72 h. From
this additional data processing it appears that the activity of
CNF1, in C2C12 cells maintained in DM, was exerted mainly
on the RhoA GTPase, as CNF1 induced a prompt and strong
relative activation of the protein, which, instead, seems to be
inactivated in response to differentiation stimuli. On the other
hand, the effects of CNF1 on Rac1 and, even more, on Cdc42,
became evident only much later, when C2C12 were expected
to be fully committed.
Time-dependent modulation of muscle markers
expression by CNF1
On the basis of the above-described results, we decided to
investigate muscle-specific gene expression kinetics in both
control and CNF1-treated C2C12 cells in relationship with the
Rho GTPase activation state at the different time points. For
this purpose, we performed a time course study on the
expression of MHC, MyoD and Myogenin in C2C12 cells
grown in DM for 3, 24 and 72 h, in the presence or absence of
CNF1. The Western blot analysis in Figure 5 clearly shows
that the MHC protein was still lacking after 24 h of challenge
with CNF1 and its accumulation after 72 h was significantly
lower than in untreated C2C12. By contrast, it appeared also
evident that CNF1 was able to induce a significant down-
regulation of MyoD and Myogenin proteins only following 72 h
of incubation in DM. Interestingly, in the first 24 h of
differentiation, only MHC was differently expressed in control
and CNF1-treated cells, suggesting a prominent interference
of CNF1 with the structural protein accumulation rather than
muscle regulatory factors.
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The ability of CNF1 to impair muscle cell
differentiation is dependent on the activation of
Rho GTPases
In order to verify whether the ability of CNF1 to impair muscle
cell differentiation required the activation of the Rho GTPases,
C2C12 cells shifted in DM were pre-exposed to the Rho-
inhibiting toxin B (CdB) from Clostridium difficile and
exoenzyme C3 from C. botulinum, before adding CNF1.
CdB acts by covalently linking a UDP-glucose at Threonine
35/37 of Rho and Rac/Cdc42, respectively,28 while C3 acts by
ADP-ribosylating Rho A, B, C proteins of the Rho subfamily at
Asn 41.29 C2C12 cells, shifted in DM, were: (i) challenged with
the inhibiting toxins alone in the absence of CNF1, for 72 h or
(ii) pretreated for 3 h with either C3 or CdB, before addition of
CNF1 for further 72 h. Data from Western blot analysis,
illustrated in Figure 6a, clearly evidenced that, although
neither CdB nor C3 alone significantly interfered with the
ability of C2C12 cells to express MHC, the effects of CNF1 on
MHC expression was considerably counteracted by CdB but
not by C3 pretreatments. This points out at Rac/Cdc42 (but
not Rho) activation as a major player in the CNF1-induced
impairment of skeletal muscle terminal differentiation. Inhibi-
tion of the Rho subfamily by C3, although did not interfere with
MHC expression, however, rendered C2C12 cells unable to
fuse into multinucleated myotubes. In fact, the majority of the
thin and elongated MHC-positive cells shown in Figure 6b
contained only one or two nuclei. This last result suggests that
Rho protein is dispensable for the biochemical differentiation
of C2C12 cells but is required in the fusion process. The small
amount of Rho-GTP detectable by pull down assays at 72 h in
DM (Figure 4a) is conceivably critical for this last phase of
skeletal muscle differentiation.
Discussion
In the current article, we provide a novel view on the role of
Rho GTPases in muscle cell differentiation, by identifying in
Figure 4 Activation kinetics of RhoA, Rac1 and Cdc42 GTPases. C2C12 cells were grown in GM for 24 h and then shifted in DM or in DM plus CNF1. At the indicated
time points, cells were lysed and the active forms of RhoA, Rac1 and Cdc42 present in each sample were detected by a Pull Down assay, as described in Materials and
Methods. (Line 1) Immunoblots showing the kinetics of RhoA (a), Rac1 (b) and Cdc42 (c) activation (upper panels) in untreated and CNF1-treated C2C12 cells. The total
amount of RhoA, Rac1 and Cdc42 proteins loaded in the assay was determined by Western blot (lower panels). Equal protein loading was confirmed by detecting b-
tubulin. (Line 2) The results in line 1 were analyzed by densitometry, as described in Materials and Methods. The histograms represent the GTPase activity normalized
for the amount of total protein loaded. The inset in (a) shows the first four columns of the histogram reported in a smaller scale. (Line 3) Graphs showing the differences in
the activation levels of RhoA, Rac1 and Cdc42 between CNF1-treated and control cells, at 3, 24 and 72 h in DM. Data are representative of three independent
experiments
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the Rho activation/deactivation balance one of the crucial
aspects that guide the skeletal differentiation program.
Also importantly, we propose a new strategy to influence
the myogenic process, in a pharmacologically way, by means
of well-characterized protein toxins that hijack the Rho
proteins.
On the whole, our results demonstrate the existence of an
antagonism between Rho and Rac/Cdc42 activities during
C2C12 cell differentiation. It was evident indeed a balance
between the two subfamilies Rho and Rac/Cdc42, the level of
Rho-GTP mirroring first Cdc42 and then Rac. After 24 h in DM,
Cdc42-GTP level significantly increased while Rho-GTP
decreased, all this apparently being correlated with the
appreciably increased expression of MyoD and appearance
of myogenin. At 72 h, when C2C12 cells achieved fully
differentiated state, levels of Cdc42-GTP remained high,
while Rac-GTP dramatically decreased and Rho-GTP in-
creased. Such changes in the ratio between activated Rho
GTPases subfamilies corresponded to a further increase of
myogenin expression and very high levels of MHC protein in
multinucleated myotubes. These findings suggest that Cdc42/
Rho balance would control the early events of the differentia-
tive cascade whereas Rac/Rho balance plays a part in the
latest. Pioneering studies in serum-starved Swiss 3T3
fibroblasts have shown a hierarchical, linear cascade of
activation linking Cdc42 signalling to activation of Rac and
then Rho.30,31 The current wisdom, however, is that the
different Rho GTPase pathways antagonize rather than
activate each other. Indeed, Rac and Cdc42 produce different
cellular responses and their activity has been reported as
antagonistic to that of Rho in different cell types. In fibroblasts,
activation of Rac has been shown to downregulate Rho
activity32 and, where Cdc42 and Rac promote membrane
protrusions, Rho promotes membrane retraction through
contractile actin and myosin filaments.7 In neuronal cells,
Cdc42 and Rac are positive regulators of neurite outgrowth,
whereas Rho inhibits neurite extension.33 Not only Rho- and
Rac/Cdc42-induced phenotypes appear mutually exclusive,
but also Rho- and Rac/Cdc42-mediated pathways regulate
each other. Such a phenotypic antagonism reflects their
activation state in various cell types, where the levels of active
Rac/Cdc42 are inversely correlated to the levels of active Rho.
This is true, for example, in epithelial cells that are growing or
undergoing cadherin-dependent cell–cell contact forma-
tion32,34 and in fibroblasts during spreading onto fibronectin.35
Of importance, regulatory pathways can target either the
switch mechanism36 or a GTPase effector pathway32,37 with a
similar outcome. Interestingly, a well-defined temporal activa-
tion/deactivation of Rho proteins in response to a single
stimulus has been reported during the clustering of acetylcho-
line receptors (Ach-R), induced by agrin in muscle cells.38 In
this case, a transient activation of Rac induces a first Ach-R
localization, while the final clustering of receptors is controlled
by Rho, and needs a deactivation of Rac. Thus, we herein
hypothesize that the maintenance of a dynamic balance
between Rho and Rac/Cdc42 activities is crucial for the
occurrence of the correct muscle cell differentiation.
Figure 5 CNF1 affects MRFs and MHC expression with a diverse kinetics.
C2C12 cells were grown in GM for 24 h and then shifted in DM or in DM plus
CNF1. At the indicated time points, cells were lysed and the expression of MHC,
MyoD and myogenin was analyzed by Western blot. The blots clearly show that
CNF1 perturbs the expression of the MRFs (MyoD and Myogenin) only following
72 h of incubation, whereas totally prevents MHC expression at 24 h, when MHC
appears in untreated C2C12. After 72 h, only very low levels of MHC are
detectable in CNF1-treated cultures although dramatically diminished if
compared with control C2C12. Equal proteins loading was confirmed by
detecting b-tubulin
Figure 6 The effects of CNF1 on muscle cell differentiation are strictly
dependent on the activation of Rho GTPases. At 24 h after seeding, C2C12 cells
were: (i) shifted in DM (DM); (ii) shifted in DM plus CNF1 (DM/CNF1); (iii) pre-
exposed in DM for 3 h to CdB or C3 before addition of CNF1 (DM/CdB/CNF1 and
DM/C3/CNF1, respectively) or (iv) treated with CdB (DM/CdB) or C3 (DM/C3)
alone in DM. Following 72 h, cells were processed for MHC detection either by
Western blot (a) or by immunofluorescence (b). Pretreatment with CdB, but not
with C3, is able to partially counteract the effects of CNF1 on MHC accumulation.
Note that C3-treated cells (DM/C3) are still able to express MHC (a) but fail to
fuse into multinucleated myotubes, being the majority of cells in this sample
mononucleated or binucleated (b). In (a), equal proteins loading was confirmed
by detecting b-tubulin. In (b), individual pictures of the same field, taken with a
DC camera, were merged using a LEICA Microsystems Imaging Equipment.
Bar¼ 20 mm
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The herein described overall effect of CNF1 on the
myogenic process supported the previously reported notion
of a general negative regulation of Rac1/Cdc42 on myogen-
esis.10–12,39 The challenge with CNF1 also indicates that the
Rho GTPases must be activated several folds with respect to
the basal levels to exert their negative control.10 In fact, we
have observed a discrete level of activated Rac1/Cdc42
during the first 24 h after differentiation induction, suggesting
that Rac/Cdc42 activation is consistent with, and probably
required for, early steps of skeletal muscle differentiation. This
assumption is also supported by previous reports indicating
that dominant-negative forms of Rac1 and Cdc42 cause the
complete failure of terminal myogenic differentiation.11,13,40 In
this paper, we also demonstrated that CNF1 induced a
temporally different and defined activation kinetics of RhoA,
Rac1 and Cdc42, in C2C12 muscle cells undergoing
differentiation. Indeed, it is worth noting that the timing of
activation and the type of Rho GTPases involved in the cell
response to CNF1 varies depending on the cell type. In
bladder cells, CNF1-induced activation of Rho GTPases is a
transient phenomenon, maximal for Rac.19 The activation of
Rac correlates with the increase of susceptibility of deami-
dated form to ubiquitin/proteasome-mediated degradation
and is followed by an impressive migratory activity of cells.19
On the other hand, in epithelial cells from larinx, we have
demonstrated that the Rac-GTP, whose level is augmented
by CNF1, acts as a pivotal molecule in the activation of the
transcription factor nuclear factor-kB (NF-kB).41 In endothelial
cells, CNF1 stimulation induced myosin light chain (MLC)
phosphorylation that was due to Rho but not Rac or Cdc42
activity.25 In C2C12 cells undergoing differentiation, in the first
24 h, CNF1 augmented nearly 10-fold the level of RhoA-GTP
and two-fold Rac1-GTP without changing Cdc42-GTP level.
At this time, CNF1 was unable to influence MyoD and
myogenin expression although interfered with MHC accumu-
lation. MyoD and myogenin expression diminished only after
72 h of CNF1 exposure, when both Rac and Cdc42 activation
levels were dramatically increased. All this further supports
our hypothesis of a connection existing between Cdc42
activation levels and MyoD/myogenin expression. Rho-GTP
was also further increased by CNF1 at 72 h, although this
appeared irrelevant for MRFs expression, as it already
occurred at 24 h when both MyoD and Myogenin levels were
comparable to those present in untreated cultures.
Consistent with the last finding, the experiments carried out
with the Rho-inhibiting C3 clearly showed a minor role (if any)
of RhoA in regulating the expression of biochemical differ-
entiation markers. Our observations are conflicting with data
reported by other authors, which envisage a positive role for
RhoA in myogenesis.8,9,27,42,43 In contrast, here we show that
activated Rho subfamily was detectable only in proliferating
C2C12 cells and in fully differentiated myotubes (72 h DM);
inhibition of Rho by C3 transferase had no effect on
expression of structural muscle markers, indicating that the
pathways governing biochemical differentiation do not require
Rho activity. On the contrary, activated Rho appears to have a
prominent role in the fusion process, as C3-treated C2C12
myocytes failed to fuse into multinucleated myotubes. The
different effects of C3 on myoblast fusion and MHC expres-
sion indicate the existence of a (at last) bifurcating pathway
acting on the myogenic program. Interestingly, in contrast with
the dramatic effects on the fusion process caused by C3-
induced Rho inhibition, the simultaneous inhibition of the
whole Rho family (Rho/Rac/Cdc42) provoked by CdB did not
seemingly act on the fusion process (data not shown). This
apparent discrepancy can be explained with and support also
our assumption that Rho somehow can balance the Rac/
Cdc42 activity during the myogenic differentiation. In fact,
CdB was able to counteract the drop in MHC content caused
by CNF1 in differentiating myocytes, clearly indicating that the
MHC expression was strictly dependent on the activation
state of the Rho proteins.
In our view, the discrepancy existing among statements
from different authors on the role of Rho GTPases in muscle
cell differentiation likely depends on transfection strategies
widely used by the researchers involved in this field. For
instance, cell-transfection using different mutants of members
of Rho family could interfere with different downstream
pathways, as demonstrated in cells other than myoblasts.44,45
Moreover, a different level of Rho activation caused by diverse
transfection approaches can lead to a completely different
response.10,13 The main advantage of our strategy that entails
the use of protein toxins, with respect to transfection assays,
resides in the ability of the toxins we have dealt with to enter
the whole-cell population and to allow, at the doses used, the
survival and activity of the ‘touched’ cells for a period of time
longer than that of transfected cells. Besides, by means of
toxins we have had the possibility to define the temporal
occurrence in which a member of the Rho family plays its role
in muscle differentiation, a question that transfection experi-
ments have so far left unanswered. Hence, by CNF1, we
provide new insights in understanding the puzzling role played
by different members of the Rho family during myogenesis.
Also, our results demonstrate that a clearcut activation/
deactivation balance of Rho family members is mandatory
to correctly accomplish terminal differentiation in C2C12 cells.
As a long-term goal, we hypothesize the possibility to use a
natural product, such as a protein toxin, to modulate also in
vivo muscle cell differentiation, a process that is fundamental
for human health.
Materials and Methods
Cells and bacterial toxins
C2C12 cells, a myogenic cell line derived from mouse muscle satellite
cells, were grown in Dulbecco’s modified Eagle’s medium (DMEM)
(GIBCO) supplemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, 0.05 IU/ml penicillin and 0.05 IU/ml streptomycin (GM) in a
humidified atmosphere of 5% CO2 at 371C. For all experiments, cells were
seeded in GM at a density of 2 104 cells/cm2. Terminal differentiation
was induced, 24 h after seeding, by shifting C2C12 cells into DM (DMEM
supplemented with 0.5% FBS).
CNF1 was purified as previously described46 from 392 ISS E. coli strain
(kindly provided by V Falbo, ISS, Rome, Italy). Clostridium difficile toxin B
(CdB) was generously provided by MR Popoff (Institute Pasteur, Paris,
France). The exoenzyme C3 was a kind gift from P Boquet (INSERM
U452, Nice, France).
CNF1 was used at the final concentration of 1010 M, CdB at 2.5 pg/ml
and C3 at 20mg/ml.
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Scanning electron microscopy (SEM)
Following treatments, cells were fixed with 2.5% glutaraldehyde in 0.1 M
cacodylate buffer (pH 7.4) at room temperature for 20 min. Following
postfixation in 1% OsO4 for 30 min, cells were dehydrated through graded
ethanols, critical point dried in CO2 and gold coated by sputtering. The
samples were examined with a Cambridge 360 scanning electron
microscope.
Fluorescent MHC and F-actin detection
A mouse monoclonal antibody (MF20) that recognizes the skeletal muscle
MHC47 (kindly provided by D Fishman, Cornell University, New York) was
used to assess terminal differentiation in C2C12 cells. Cells were fixed in
cold methanol : acetone (1 : 1) for 10 min and permeabilized in 0.25%
Triton X-100 in PBS. Cells were then incubated with the MF20 supernatant
for 30 min at 371C, followed by incubation with a fluoresceine-conjugate
goat anti-mouse antibody (Cappel/ICN) diluted 1 : 800, for 30 min at 371C.
For F-actin visualization, cells were fixed in 3.7% paraformaldehyde in
PBS (pH 7.4) for 10 min and permeabilized in 0.25% Triton X-100 in PBS
for 5 min. Cells were stained with fluoresceine-conjugate phalloidin
(Sigma) used at the final concentration of 0.5mg/ml for 30 min at 371C.
Nuclei were stained with 0.2 mg/ml DAPI dye (Sigma) for 3 min at room
temperature.
Protein extraction and Western blot
Cells were lysed in boiled Sample Buffer 1 (50 mM Tris-HCl pH 6.8, 2%
SDS, 10% glycerol, 100 mM DTT). In total, 25 mg of total protein extracts
were resolved on 8 or 12% SDS-PAGE (according to the different
molecular weights) and electrically transferred onto nitrocellulose
membranes. Membranes were blocked with TBS-T (20 mM Tris-HCl (pH
7.4), 150 mM NaCl, 0.02% Tween-20) containing 5% skimmed milk (BIO-
RAD), for 30 min at room temperature, and then incubated overnight at
41C with primary antibodies diluted in TBS-T containing 2% milk. The
following antibodies were used: monoclonal anti-MHC antibody MF20
(Bader et al.47; a kind gift of D Fishmann), 1 : 10; monoclonal antimyogenin
antibody IF5D (Wright et al.48; made available by G Cossu), 1 : 5; rabbit
polyclonal anti-MyoD antibody, R3B2, diluted 1 : 1000 (raised in
collaboration with S Alema`, ICB, CNR, Rome, Italy and M Crescenzi,
ISS, Rome, Italy, against murine MyoD expressed in bacteria); mouse
monoclonal anti b-tubulin (ICN) diluted 1 : 5000. After extensive washing,
immunecomplexes were detected with horse-radish peroxidase con-
jugated species-specific secondary antibodies (BIO-RAD) followed by
enhanced chemiluminescence reaction (Amersham).
Activated Rho GTPase pull-down
Pull-down assay was performed as previously described.49,50 Cells were
lysed in: (i) 50 mM HEPES (pH 7.4), 0.5% sodium deoxycholate, 1%
NP40, 0.1% SDS, 0.5 M NaCl, 10 mM MgCl2, plus protease inhibitors (to
detect Rho-GTP); or (ii) 50 mM HEPES (pH 7.3), 0.1 M NaCl, 10 mM
MgCl2, 5% glycerol, 1% NP40, 10 mM NaF, plus protease inhibitors (to
detect Rac/Cdc42-GTP). The cleared lysates were incubated with 80 mg of
GST-PAK-CD (for Rac/Cdc42) and GST-Rhotekin (for Rho) fusion
proteins, bound to glutathione-coupled Sepharose beads (Amersham) for
40 min at 41C. Beads were washed three times in: (i) 50 mM HEPES (pH
7.4), 0.5% sodium deoxycholate, 1% NP40, 0.1% SDS, 0.25 M NaCl,
5 mM MgCl2, plus protease inhibitors (for Rho); or (ii) 50 mM HEPES (pH
7.3), 0.1 M NaCl, 10 mM MgCl2, 5% glycerol, 0.5% NP40, 10 mM NaF,
plus protease inhibitors (for Rac/Cdc42). The bound proteins were eluted
in Sample buffer before being subjected to SDS-PAGE and immunoblot-
ting with the following specific antibodies: polyclonal anti-RhoA (Santa
Cruz Biotecnology) 1 : 1000, monoclonal anti-Rac1 (Transduction
Laboratories) 1 : 3500 and monoclonal anti-Cdc42 (Santa Cruz Biotecnol-
ogy) 1 : 500. Whole-cell lysates (2% of input) were analyzed in parallel.
Autoradiographs, scanned using the Imaging Densitometer GS-700
(BIO-RAD), were quantified by means of Multianalist software and
normalized as a function of the total proteins loaded in the assay.
Northern blot analysis
Total RNA was prepared and analyzed as described.51 For detection of
muscle-specific and constitutive transcripts, inserts were excised with the
appropriate restriction enzymes from the following plasmids and used as
probes: pMHC-25, containing a 0.6 kb cDNA fragment encoding the
mouse skeletal MHC (kindly provided by D Fishman, Cornell University,
New York); pEMC11S containing a 1.5 kb mouse MyoD cDNA (obtained
from H Weintraub); pEMSV-mgn, containing a 1.5 kb cDNA fragment
encoding the rat Myogenin48 (made available by V Sorrentino); a plasmid
containing a 1.2 kb cDNA fragment of the avian glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) (obtained from C Schneider, CIB,
Trieste, Italy).
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